Medscape is available in 5 Language Editions – Choose your Edition here.


Mycoplasmal Pneumonia

  • Author: Michael Joseph Bono, MD, FACEP; Chief Editor: Ryland P Byrd, Jr, MD  more...
Updated: Sep 05, 2014


Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP), and the disease usually has a prolonged, gradual onset.[1] M pneumoniae was first isolated in cattle with pleuropneumonia in 1898.

In 1938, Reimann described the first cases of mycoplasmal pneumonia in man and coined the term "primary atypical pneumonia" after observing 7 patients in Philadelphia with marked constitutional symptoms, upper and lower respiratory tract symptoms, and a protracted course with gradual resolution.[2] Peterson discovered the phenomenon of cold agglutinin in 1943. High titers of cold agglutinins in patients with primary atypical pneumonia were discovered accidentally. In 1944, Eaton was credited with discovering a specific agent, coined Eaton's agent, as the principal cause of primary atypical pneumonia.[3] First thought to be a virus, Eaton's agent was proved to be a Mycoplasma species in 1961.

The breakdown of the Mollicutes class, which includes the Mycoplasma genus, is presented in the image below.

Diagram of the Mollicutes class, to which the MycoDiagram of the Mollicutes class, to which the Mycoplasma genus belongs.

Go to Community-Acquired Pneumonia, Bacterial Pneumonia, Mycoplasma Infections, and Imaging Atypical Bacterial Pneumonia for more information on these topics.



The organism responsible for mycoplasmal pneumonia, M pneumoniae, is a pleomorphic organism that, unlike bacteria, lacks a cell wall, and unlike viruses, does not need a host cell for replication. The prolonged paroxysmal cough seen in this disease is thought to be due to the inhibition of ciliary movement. M pneumoniae has a remarkable gliding motility and specialized tip organelles that allows it to burrow between cilia within the respiratory epithelium, eventually causing sloughing of the respiratory epithelial cells.

The organism has two properties that seem to correlate well with its pathogenicity in humans. The first is a selective affinity for respiratory epithelial cells and the second is the ability to produce hydrogen peroxide, which is thought to be responsible for much of the initial cell disruption in the respiratory tract and for damage to erythrocyte membranes.

The pathogenicity of M pneumoniae has been linked to the activation of inflammatory mediators, including cytokines. One study reported on an emergence of drug-resistant M pneumoniae infection. However, the study concluded that host immune maturity and not the virulence factor of the organism is a major determinant factor of disease severity.[4] Macrolide-resistant M pneumoniae has emerged in adult community-acquired pneumonia[5] as well as pediatric pneumonia.[6]

Mycoplasma pneumoniae has been identified with an increasing array of illnesses, such as acute hepatitis,[7, 8] immune thrombocytopenic purpura,[9] severe autoimmune hemolytic anemia,[10] Stevens-Johnson syndrome,[11, 12] arthritis,[13] and transverse myelitis.[14, 15]



The causative agent of mycoplasmal pneumonia is M pneumoniae, a bacterium in the shape of a short rod, lacking a cell wall, which belongs to the class Mollicutes, the smallest known free-living microorganisms. The organism can be excreted from the respiratory tract for several weeks after the acute infection; therefore, isolation of the organism may not indicate acute infection. The organism is difficult to grow in the laboratory, requiring not only specialized growth medium, but also long growth times, which limits the clinical utility of culturing the organism.



M pneumoniae is now recognized as one of the most common causes of community-acquired pneumonia in otherwise healthy patients younger than 40 years. Although mycoplasmal pneumonia is common in all age groups, it is most common in the first 2 decades of life, is rare in children younger than five years, and has the highest rate of infection in individuals aged 5-20 years. Although no difference in disease frequency is observed between males and females, illnesses are somewhat more severe in males.

M pneumoniae causes upper and lower respiratory illness in all age groups, particularly in temperate climates, and can occur at any time of the year, but large outbreaks tend to occur in the late summer and fall. Transmission of the organism is person-to-person by infected respiratory droplets. In summer, this organism may cause as many as 50% of all pneumonias.

The incubation of mycoplasmal pneumonia tends to be smoldering and averages a period of 2-3 weeks, in contrast to that of influenza and other viral pneumonias, which generally average a few days. Epidemics of mycoplasmal pneumonia tend to occur every 4-8 years in the general population and tend to be more frequent within closed populations, such as in military and prison populations. Although M pneumoniae is a common cause of pneumonia, only 5-10% of infected patients actually develop pneumonia. Many patients infected with M pneumoniae remain asymptomatic, but patients who become symptomatic develop a respiratory infection which can be lingering and quite bothersome.



With proper treatment, a full recovery is expected. In almost all patients, the pneumonia resolves without any serious complications. However, M pneumoniae can cause severe pneumonia in children and has recently been associated with acute chest syndrome in patients with sickle cell anemia.[16] Immunity after infection with M pneumoniae is not long lasting.

Contributor Information and Disclosures

Michael Joseph Bono, MD, FACEP Professor of Emergency Medicine, Vice Chair, Emergency Medicine Residency Program, Department of Emergency Medicine, Eastern Virginia Medical School

Michael Joseph Bono, MD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, Medical Society of Virginia, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Paul Blackburn, DO, FACOEP, FACEP Attending Physician, Department of Emergency Medicine, Maricopa Medical Center

Paul Blackburn, DO, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, Arizona Medical Association, American College of Osteopathic Emergency Physicians, American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University

Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

  1. McCormack WM. Infections due to Mycoplasmas. Kasper DL, Braunwald E, Fauci AS, et al, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2005. 16th ed.: 1008-11, 159.

  2. Reimann HA. An acute infection of the respiratory tract with atypical pneumonia: a disease entity probably caused by a filtrable virus. JAMA. 1938. 111:2377-84.

  3. Eaton MD, Meiklejohn G, VanHerick W. Studies on the etiology of primary atypical pneumonia: a filterable agent transmissible to cotton rats, hamsters, and chick embryos. J Exp Med. 1944. 79:649-67.

  4. Kamizono S, Ohya H, Higuchi S, Okazaki N, Narita M. Three familial cases of drug-resistant Mycoplasma pneumoniae infection. Eur J Pediatr. 2010 Jun. 169(6):721-6. [Medline].

  5. Isozumi R, Yoshimine H, Morozumi M, Ubukata K, Ariyoshi K. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae. Respirology. 2009 Nov. 14(8):1206-8. [Medline].

  6. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009 Dec. 15(6):380-3. [Medline].

  7. Lee SW, Yang SS, Chang CS, Yeh HJ, Chow WK. Mycoplasma pneumonia-associated acute hepatitis in an adult patient without lung infection. J Chin Med Assoc. 2009 Apr. 72(4):204-6. [Medline].

  8. Quioc JJ, Trabut JB, Drouhin F, Malbrunot C, Vallet-Pichard A, Pol S, et al. Acute cholestatic hepatitis revealing Mycoplasma pneumoniae infection without lung involvement in an adult patient. Eur J Gastroenterol Hepatol. 2009 Feb. 21(2):220-1. [Medline].

  9. Okoli K, Gupta A, Irani F, Kasmani R. Immune thrombocytopenia associated with Mycoplasma pneumoniae infection: a case report and review of literature. Blood Coagul Fibrinolysis. 2009 Oct. 20(7):595-8. [Medline].

  10. Khan FY, A yassin M. Mycoplasma pneumoniae associated with severe autoimmune hemolytic anemia: case report and literature review. Braz J Infect Dis. 2009 Feb. 13(1):77-9. [Medline].

  11. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010 Feb. 85(2):131-8. [Medline]. [Full Text].

  12. Yachoui R, Kolasinski SL, Feinstein DE. Mycoplasma pneumoniae with atypical stevens-johnson syndrome: a diagnostic challenge. Case Rep Infect Dis. 2013. 2013:457161. [Medline]. [Full Text].

  13. Azumagawa K, Kambara Y, Murata T, Tamai H. Four cases of arthritis associated with Mycoplasma pneumoniae infection. Pediatr Int. 2008 Aug. 50(4):511-3. [Medline].

  14. Csábi G, Komáromy H, Hollódy K. Transverse myelitis as a rare, serious complication of Mycoplasma pneumoniae infection. Pediatr Neurol. 2009 Oct. 41(4):312-3. [Medline].

  15. Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol. 2009 Sep. 41(3):159-66. [Medline].

  16. Neumayr L, Lennette E, Kelly D, Earles A, Embury S, Groncy P, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics. 2003 Jul. 112(1 Pt 1):87-95. [Medline].

  17. Wang K, Gill P, Perera R, Thomson A, Mant D, Harnden A. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev. 2012 Oct 17. 10:CD009175. [Medline].

  18. Mellick LB, Verma N. The Mycoplasma pneumoniae and bullous myringitis myth. Pediatr Emerg Care. 2010 Dec. 26(12):966-8. [Medline].

  19. Kotikoski MJ, Kleemola M, Palmu AA. No evidence of Mycoplasma pneumoniae in acute myringitis. Pediatr Infect Dis J. 2004 May. 23(5):465-6. [Medline].

  20. Palmu AA, Kotikoski MJ, Kaijalainen TH, Puhakka HJ. Bacterial etiology of acute myringitis in children less than two years of age. Pediatr Infect Dis J. 2001 Jun. 20(6):607-11. [Medline].

  21. Roberts DB. The etiology of bullous myringitis and the role of mycoplasmas in ear disease: a review. Pediatrics. 1980 Apr. 65(4):761-6. [Medline].

  22. Reittner P, Müller NL, Heyneman L, Johkoh T, Park JS, Lee KS, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol. 2000 Jan. 174(1):37-41. [Medline].

  23. Ma LD, Chen B, Dong Y, Fan J, Xia L, Wang SZ, et al. Rapid mycoplasma culture for the early diagnosis of Mycoplasma pneumoniae infection. J Clin Lab Anal. 2010. 24(4):224-9. [Medline].

  24. Dumke R, Strubel A, Cyncynatus C, Nuyttens H, Herrmann R, Lück C, et al. Optimized serodiagnosis of Mycoplasma pneumoniae infections. Diagn Microbiol Infect Dis. 2012 Jun. 73(2):200-3. [Medline].

  25. Zhao F, Cao B, He LH, et al. Evaluation of a new real-time PCR assay for detection of Mycoplasma pneumoniae in clinical specimens. Biomed Environ Sci. 2012 Feb. 25(1):77-81. [Medline].

  26. Mustafa MI, Al-Marzooq F, How SH, Kuan YC, Ng TH. The use of multiplex real-time PCR improves the detection of the bacterial etiology of community acquired pneumonia. Trop Biomed. 2011 Dec. 28(3):531-44. [Medline].

  27. Di Marco E, Cangemi G, Filippetti M, Melioli G, Biassoni R. Development and clinical validation of a real-time PCR using a uni-molecular Scorpion-based probe for the detection of Mycoplasma pneumoniae in clinical isolates. New Microbiol. 2007 Oct. 30(4):415-21. [Medline].

  28. Gullsby K, Storm M, Bondeson K. Simultaneous detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae by use of molecular beacons in a duplex real-time PCR. J Clin Microbiol. 2008 Feb. 46(2):727-31. [Medline]. [Full Text].

  29. Chen CJ, Hung MC, Kuo KL, Chung JL, Wu KG, Hwang BT, et al. The role of eosinophil cationic protein in patients with Mycoplasma pneumoniae infection. J Chin Med Assoc. 2008 Jan. 71(1):37-9. [Medline].

  30. Llibre JM, Urban A, Garcia E, Carrasco MA, Murcia C. Bronchiolitis obliterans organizing pneumonia associated with acute Mycoplasma pneumoniae infection. Clin Infect Dis. 1997 Dec. 25(6):1340-2. [Medline].

  31. Nagashima M, Higaki T, Satoh H, Nakano T. Cardiac thrombus associated with Mycoplasma pneumoniae infection. Interact Cardiovasc Thorac Surg. 2010 Dec. 11(6):849-51. [Medline].

  32. Li CM, Gu L, Yin SJ, et al. Age-specific Mycoplasma pneumoniae pneumonia-associated myocardial damage in children. J Int Med Res. 2013 Oct. 41(5):1716-23. [Medline].

  33. Daxboeck F. Mycoplasma pneumoniae central nervous system infections. Curr Opin Neurol. 2006 Aug. 19(4):374-8. [Medline].

  34. Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila). 2000 Apr. 39(4):195-201. [Medline].

  35. Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis. 1993 Aug. 17 Suppl 1:S52-7. [Medline].

  36. Luby JP. Pneumonia caused by Mycoplasma pneumoniae infection. Clin Chest Med. 1991 Jun. 12(2):237-44. [Medline].

  37. Khan FY, Sayed H. Rhabdomyolysis associated with Mycoplasma pneumoniae pneumonia. Hong Kong Med J. 2012 Jun. 18(3):247-9. [Medline].

  38. Oishi T, Narita M, Ohya H, et al. Rhabdomyolysis associated with antimicrobial drug-resistant Mycoplasma pneumoniae. Emerg Infect Dis. 2012 May. 18(5):849-51. [Medline]. [Full Text].

  39. Liu EM, Janigian RH. Mycoplasma pneumoniae: the other masquerader. JAMA Ophthalmol. 2013 Feb. 131(2):251-3. [Medline].

  40. Smith LG. Mycoplasma pneumonia and its complications. Infect Dis Clin North Am. 2010 Mar. 24(1):57-60. [Medline].

  41. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014 Jun. 133(6):1081-90. [Medline].

  42. Colin AA, Yousef S, Forno E, Korppi M. Treatment of Mycoplasma pneumoniae in pediatric lower respiratory infection. Pediatrics. 2014 Jun. 133(6):1124-5. [Medline].

  43. Cardinale F, Chironna M, Chinellato I, Principi N, Esposito S. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol. 2013 Feb. 51(2):723-4. [Medline]. [Full Text].

  44. Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother. 2013 May. 57(5):2252-8. [Medline]. [Full Text].

  45. Uh Y, Hong JH, Oh KJ, et al. Macrolide resistance of Mycoplasma pneumoniae and its detection rate by real-time PCR in primary and tertiary care hospitals. Ann Lab Med. 2013 Nov. 33(6):410-4. [Medline]. [Full Text].

  46. Brown SM, Padley S, Bush A, Cummins D, Davidson S, Buchdahl R. Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors. Pediatr Pulmonol. 2008 Feb. 43(2):200-2. [Medline].

  47. Drugs of choice for community-acquired bacterial pneumonia. Med Lett Drugs Ther. 2007 Jul 30. 49(1266):62-4. [Medline].

  48. Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis. 1993 Aug. 17 Suppl 1:S52-7. [Medline].

  49. Yang E, Altes T, Anupindi SA. Early Mycoplasma pneumoniae infection presenting as multiple pulmonary masses: an unusual presentation in a child. Pediatr Radiol. 2008 Apr. 38(4):477-80. [Medline].

Diagram of the Mollicutes class, to which the Mycoplasma genus belongs.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.